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Abstract
Proper care of patients with bone metastasis requires interdisciplinary treatments.
Radiotherapy (RT) plays a central role in the management of painful bone metastasis.
External beam RT can provide rapid successful palliation of painful bone metastasis in
50–80% of patients, is associated with very few adverse effects and leads to complete
pain relief at the treated site in up to one-third of patients. Intensity-modulated RT
(IMRT) or stereotactic body RT (SBRT) enables the delivery of higher doses to the target
tumor while minimizing the dose to adjacent organs. Reirradiation using IMRT or SBRT
is a valuable option for the management of bone metastases. A multidisciplinary team,
especially one consisting of a spinal surgeon and rehabilitation physician, is particularly
useful for treating patients with spinal bone metastases characterized by spinal instabil-
ity. Rehabilitation intervention which increases the physical activity level and prevents
deconditioning is important. Future developments in surgical procedures and RT will
likely improve the management protocols for bone metastases and technology to reduce
metal artifacts in radiation planning might improve the efficacy and safety of combina-
tion therapy.
Keywords: spinal metastases, intensity-modulated radiotherapy, rehabilitation,
multidisciplinary team, stereotactic body radiotherapy
1. Introduction
Bone metastases are a common manifestation of malignancies that can cause severe and
debilitating effects, including pain, spinal cord compression, hypercalcemia and pathologic
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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distribution, and reproduction in any medium, provided the original work is properly cited.
fractures. Proper care of patients with bone metastasis requires interdisciplinary treatments
delivered by orthopedic surgeons, radiation oncologists, rehabilitation specialists, medical
oncologists, pain medicine specialists, radiologists and palliative care professionals. Radiother-
apy (RT) has played a central role for palliation of painful bone metastasis, leading to complete
pain relief at the treated site in up to one-third of patients [1]. The role of RT and radio-
therapeutic techniques using a multidisciplinary approach for the treatment of bone metasta-
ses have been discussed recently.
2. Indications and optimal doses for bone metastases RT
External beamRT (EBRT) continues to be themainstay treatment for painful, uncomplicated, bone
metastases. EBRT can provide rapid successful palliation of painful bone metastasis in 50–80% of
patients, is associatedwith very fewadverse effects and leads to complete pain relief at the treated
site in up to one-third of patients. Although various fractionation schemes can provide good
palliation rates, numerous prospective randomized trials have shown that 30 Gy in 10 fractions,
24 Gy in 6 fractions, 20 Gy in 5 fractions, or 8 Gy in a single fraction provide excellent pain control
with minimal side effects (Table 1) [2–7]. Longer fractionated courses have the advantage of a
lower incidence of repeat irradiation to the same site, whereas single fractions have proved more
convenient for patients and caregivers. In addition, repeat irradiation with EBRT might be safe,
effective and less commonly necessary in patientswith a short life expectancy.
Author Patients
(n)
Dose and fractions Overall pain
relief (%)
Complete
response (%)
Acute
toxicity (%)
Late
toxicity (%)
Repeat
treatment
rate (%)
BPTWP [2] 775 8 Gy in 1 Fx 78 57 30 2 23
20 Gy in 5 Fx/30 Gy
in 10 Fx
78 58 32 1 10
Foro [3] 160 8 Gy in 1 Fx 75 15 13 NA 28
30 Gy in 10 Fx 86 13 18 NA 2
Hartsell [4] 898 8 Gy in 1 Fx/30 Gy in
10 Fx
66 15 10 4 18
Nielsen [5] 241 8 Gy in 1 Fx 62 15 35 5 21
20 Gy in 4 Fx 71 15 35 5 12
Roos [6] 272 8 Gy in 1 Fx 53 26 5 5 29
20 Gy in 5 Fx 61 27 11 4 24
Steenland [7] 1171 8 Gy in 1 Fx 72 37 Equivalent 4 25
24 Gy in 6 Fx 69 33 Equivalent 2 7
BPTWP, Bone Pain Trial Working Party; NA, not assessed; Fx, fraction(s).
Table 1. Outcomes of single fraction or multifraction external beam radiotherapy for painful bone metastases.
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For metastatic spinal cord compression (MSCC), EBRT is the standard of care. Although a total
of 30 Gy in 10 fractions is the most frequently employed fractionation schedule, multiple
fractionation schemes have been reported, which undoubtedly reflect the heterogeneity in
patient populations and tumor histologies (Table 2) [8–11]. In a retrospective study, Rades et al.
[11] suggested that dose escalation beyond 30 Gy in 10 fractions did not improve motor
function and local control in patients with MSCC who had radioresistant tumors such as renal
cell carcinomas, colorectal cancers and malignant melanomas. However, in patients with
breast cancer, prostate cancer, myeloma or lymphoma and others who had a favorable prog-
nosis, dose escalation beyond 30 Gy provided better local control and extended overall sur-
vival [10]. Therefore, the use of 30 Gy in 10 fractions could be regarded as the standard
therapeutic dose for MSCC, although the available evidence is limited. In patients with a
favorable survival prognosis, dose escalation beyond 30 Gy might improve local control and
overall survival, but it might not improve functional outcome and dose escalation to 40 Gy in
20 fractions might be insufficient against radioresistant tumors.
3. Intensity-modulated RTor stereotactic body RT for bone metastases
Recently, intensity-modulated RT (IMRT) or stereotactic body RT (SBRT) has been applied
for spinal bone metastases and the development of systemic treatments has improved
Author Study
design
State of
disease
Dose Ambulatory rate
before treatment
(%)
Motor function
improvement
(%)
Local
control
Overall
survival
Maranzano
[8]
RCT Unfavorable
prognosis
8 Gy in 1 Fx 64 12 NA 4 months
(median)
16 Gy in 2 Fx 67 21 NA 4 months
(median)
Rades [9] Prospective
non-RCT
Various
tumors
8 Gy in 1 Fx/20
Gy in 4 Fx
61 37 61% at
1 year
23% at 1
year
30–40 Gy in
10–20 Fx
62 39 81% at
1 year
30% at 1
year
Rades [10] Matched
cohort
Favorable
prognosis
tumors
30 Gy in 10 Fx 85 40 71% at
2 years
53% at 2
years
37.5 Gy in 15
Fx/40 Gy in 20
Fx
85 41 92% at
2 years
68% at 2
years
Rades [11] Retrospective Radioresistant
tumors
30 Gy in 10 Fx 62 18 76% at
1 year
NA
37.5 Gy in 15
Fx40 Gy in 20
Fx
63 22 80 % at
1 year
NA
RCT, randomized controlled trial; Fx, fraction(s); NA, not assessed.
Table 2. External beam radiotherapy outcomes for metastatic spinal cord compression.
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survival in patients with bone metastasis. However, in such cases, the standard regimens
for bone metastases including 30 Gy in 10 fractions, 20 Gy in 5 fractions, or 8 Gy in a single
fraction were insufficient for long-term pain management. Therefore, to increase the dura-
tion of pain control, it might be necessary to consider more intense RT or treatment
regimens.
IMRT delivers high doses to tumor targets while decreasing the dose to organs-at-risk and,
therefore, presents a major dosimetric advantage over three-dimensional conformal RT. IMRT
took radiation treatment planning and delivery to a higher level by combining technologies. It
utilizes movement of the multileaf collimator (MLC) during the actual beam-on time to mod-
ulate, or alter, the radiation beam as it leaves the radiation treatment unit. Such beam modu-
lation allows the application of concave dose distributions. The computer system calculates an
IMRT plan incorporating several beams, or, alternatively, a moving arc arrangement with the
movement of the MLC to create a plan that achieves the radiation-dosing goals (Figure 1). On
the other hand, SBRT is emerging as an alternative RT technique to deliver dose-escalated
radiation to tumor targets. Due to the application of several nonisocentric beams, SBRT
delivers highly conformal large radiation dose fractions to target volumes with precision (<1
mm) and steep dose gradients. This allows for planning target volume reductions, thereby
minimizing exposure to critical adjacent organs, which produces a toxicity profile comparable
with that of conventionally fractionated RT, despite the use of higher doses per fraction
(Figure 2).
Figure 1. Comparison of radiation dose distributions between conventional radiotherapy and intensity-modulated radio-
therapy (IMRT). (A) The osteolytic change in the lumbar vertebral body and infiltration into the spinal canal. (B) The dose
distribution of conventional radiotherapy (two-directional anteroposterior-posteroanterior opposed irradiation at 30 Gy
in 10 fractions). (C) The distribution of IMRT using volumetric modulated arc therapy (50 Gy in 10 fractions).
Radiotherapy6
Three important factors should be considered for the decision to utilize IMRT or SBRT.
First, IMRT or SBRT must be adapted for the treatment of oligometastasis in the bone.
Long-term survival has been noted in patients diagnosed with isolated bone metastasis
[12–15]. Therefore, successful control of oligometastasis of the bone due to the delivery of
higher doses might contribute to improved treatment outcomes and quality of life (QOL).
Second, IMRT or SBRT can be performed for reirradiation of the same site. It is technically
difficult to reirradiate the same site using conventional RT. However, with IMRT or SBRT
the dose to the spinal cord or adjacent organs can be reduced to within the tolerable
range, facilitating reirradiation. Third, IMRT or SBRT can be applied for radioresistant
bone metastases. Therefore, when indicating IMRT or SBRT for metastatic bone tumors,
oncologists should consider the disease behavior and estimated life expectancy of the
patient.
The treatment outcomes of previous studies that utilized IMRT or SBRT for bone metastases
[16–19] are compared in Table 3. Each study performed IMRT or SBRT using various dose or
fractionation protocols because standard regimens have not yet been proposed. The majority
of studies demonstrated excellent local control without serious harmful phenomenon such as
myelopathy. However, because most previous studies were retrospective and sufficient evi-
dence has not yet been accumulated, any adaptation of IMRT or SBRT to deliver higher doses
must be carefully discussed for individual patients. A multidisciplinary team comprising
radiation oncologists, orthopedists, medical oncologists, radiologists, rehabilitation physicians
Figure 2. A 70-year-old male patient suffering from lung cancer with cervical vertebral bone metastasis. The schema and
dose distribution of SBRT for bone metastasis using CyberKnife treatment system. (A) The blue line indicates the beam
directions. (B) Representative dose distribution.
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and palliative care medicine doctors would be ideal for discussing and deciding treatment
options including the application of higher dose RT.
4. Assessment of instability due to spinal metastasis: surgery, RT and the
combination of both treatments
Oncologic care is improving and the survival rates of patients with various malignancies
are increasing. Since the advent of recent technologic advancements in the detection
methods used to locate new lesions and metastasis, orthopedic surgeons have been
confronted with an increasing number of patients with spinal metastasis. Such patients
can develop sudden paraplegia due to pathological fracture or tumor invasion into the
spinal canal. Patients with symptomatic spinal metastasis present with severe pain and
poor QOL [20].
If a multidisciplinary conference between radiation oncologist, spinal surgeons, physiothera-
pists and medical oncologists was developed, appropriate treatment strategies could be
discussed and implemented. For example, a patient who develops sudden paraplegia some-
times needs urgent treatment including surgical decompression. Therefore, a simple classifica-
tion method with easily assigned radiographic and patients factors could be helpful to
facilitate communication and appropriate referral among the multidisciplinary oncology team,
ensuring prompt and optimal treatment decisions.
Most cases of spinal metastasis occur in the vertebral body, intervertebral disc and anterior
and/or posterior longitudinal ligament, whereas the involvement of anatomical structures
related to spinal motion is rare. Batson's venous plexus and the avalvular vein of the vertebral
venous system play an important mechanistic role in the pathology of spinal metastasis.
Namely, all cancers with a preference toward bone metastasis, such as bronchial, breast and
prostate cancers are disseminated to the spine via these vessels. Consequently, the anterior
spinal column is the most frequent site of spinal metastases, with ∼80% of lesions appearing in
the vertebral body [21].
Authors Machine/type Dose LCR Adverse events
Murai [16] Tomotherapy/IMRT 40 Gy in 8 fx/48 Gy in 16 fx 84% (1-year) No radiation-induced
myelopathy
Yamada [17] Linear accelerator/IMRT 18–24 Gy in 1 fx 90% No radiation-induced
myelopathy
Guckenberger [18] Linear accelerator/SBRT Median24 Gy in 3 fx 84% (2-year) No radiation-induced
myelopathy
Degen [19] CyberKnife/SBRT 24 Gy in 1 fx 90% No radiation-induced
myelopathy
IMRT, intensity modulated radiotherapy; SBRT, stereotactic body radiotherapy; LCR, local control rate.
Table 3. Outcomes of IMRT or SBRT in bone metastasis.
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Instability has been classified as segmental instability, which is mostly the result of trauma
or degenerative changes, or component instability, which is caused by tumor invasion in
the vertebral body. The type of instability present should be determined when considering
the therapeutic management of spinal metastases. Therefore, specific criteria for stability
assessments are required. In 2010, Fisher et al. [22] reported a novel classification system
for spinal instability in neoplastic disease, which was established using the best evidence
provided by systematic reviews and expert opinions. The spine instability neoplastic score
(SINS) is a comprehensive classification system based on patient symptoms and radio-
graphic criteria without consideration of neurologic status, histology, or general physical
condition. The SINS considers spinal metastasis location, type, pain and lesion quality,
spinal alignment, the extent of vertebral body collapse and posterolateral spinal element
involvement. Furthermore, the predictive value of the SINS was validated by the analysis
of the clinical and radiographic data of 30 patients. The SINS score is categorized into a
three-tier system with 0–6 being stable, 7–12 being potentially unstable and 13–18 being
unstable [23]. A surgical consultation is recommended for patients with a SINS score
greater than 7.
Surgical treatment decisions are broadly based on spinal stability and patient-specific factors
including patient health, prognosis and tumor histology [24]. The surgical approach is indicated
for pathological fractures and sudden onset of neurological symptoms. The current indications
for spinal surgery are radioresistant tumors, progressive neurologic deficits lasting no longer
than 24 hours, bone fragments in the spinal canal and spinal instability due to pathologic
fracture. In addition, life expectancy should be at least 3 months. Survival duration in patients
with bone metastases is largely dependent upon controllability of the primary tumor. Several
prognostic scoring systems have been reported in an attempt to indicate the appropriate surgi-
cal strategy [24–26]. Tokuhashi et al. [24] and Tomita et al. [25] recommended that patients
expected to have a good prognosis should undergo wide excision including total en bloc
spondylectomy, those expected to have an intermediate prognosis should undergo marginal or
intralesional excision and spinal stabilization (Figure 3) and those expected to have a poor
prognosis should be managed conservatively. However, it should be emphasized that local
spinal pathology, rather than tumor histology, determines the degree of pain or severity of
neurologic deficits. The ultimate surgical goals are to obtain good QOL and activity of daily
living (ADL) scores by relieving pain and improving neurologic status (Tables 4 and 5).
Recently, a prospective analysis of the surgical outcome in 70 patients with symptomatic
spinal metastasis was conducted [27]. Laminectomy and posterior stabilization following RT
significantly improved the performance status and ADL in >95% of patients, with sustained
improvement for at least 6 months in >80%. In a randomized, multicenter, nonblinded trial
in 101 patients, Patchell et al. [28] revealed a major breakthrough for surgical treatment
followed by RT. They compared the efficacy of surgery followed by RT with that of RT
alone. Fifty patients were assigned to surgery followed by RT and 51 to RT alone. Signifi-
cantly more patients were able to walk after surgery followed by RT (84%) compared with
after RT alone (57%). Moreover, the duration of walking ability maintenance was signifi-
cantly longer in the surgery followed by RT Arm (median, 122 days) compared with the RT
alone Arm (median, 13 days).
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The complication rate after surgery can be as high as 20–30% and this must be weighed
against the intended benefits. Postsurgical complication and mortality rates were evaluated
in 26,233 patients included in the National Inpatient Sample of United States [29]. The in-
hospital mortality rate was 5.6% and the complication rate was 21.9%. Pulmonary (6.7%)
and postoperative (5.9%) hemorrhage or hematoma were the most commonly reported
complications. Complication rates were higher in older patients and those with
comorbidities including hypertension, chronic lung disease and diabetes mellitus; having a
Figure 3. Laminectomy and posterior stabilization in a 76-year-old male with C5 metastasis of thyroid cancer. A patient
presented with right deltoid muscle weakness and intractable pain in the right shoulder. The Tomita and Tokuhashi scores
were 7 and 9 points, respectively. He underwent combination spinal surgery with a C5 laminectomy and C2 to T2
posterior stabilization, and postoperative conventional radiation therapy (30 Gy in 10 fractions). (a) Preoperative com-
puted tomography. (b) and (c): Preoperative magnetic resonance imaging with T1-weighted and T2-weighted images,
respectively. (d): Intraoperative image. (e) and (f): Postoperative radiographs.
Treatment Baseline 1 month 3 months 6 months
Median PS Surgery 4 2 1 1
Nonsurgery 3 4 4 4
Mean BI Surgery 43.8 ± 28.0 74.2 ± 26.7 74.9 ± 31.8 82.5 ± 28.1
Nonsurgery 48.5 ± 31.9 37.9 ± 34.1 35.5 ± 31.0 31.7 ± 10.4
Surgery patients (n = 46), nonsurgery patients (n = 24). PS, Eastern Cooperative Oncology Group Performance Status; BI,
Barthel Index.
Table 4. Surgical outcome of performance score and activities of daily life in patients with spinal metastases.
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single comorbidity increased the risk of in-hospital death by ∼4 fold. In a retrospective
series of 123 patients treated for spinal metastases, the rate of major wound complications
(dehiscence or wound infection) was 32% in the group that underwent RT before surgery,
whereas it was 12% in the group of patients first treated using surgery. Therefore, in
patients with symptomatic MSCC, postoperative RT appeared to be more beneficial than
preoperative RT [30].
In patients with spinal bone metastasis, the goals of spinal surgery are to restore spinal
stabilization, preserve neurologic function and provide pain relief. For appropriately indicated
patients, spinal surgery can provide significant improvements in both QOL and ADL, possibly
leading to the administration of adjuvant systemic therapies.
5. Rehabilitation for bone metastasis after surgery or RT
Because of the advances in diagnostic and therapeutic technologies, the overall survival of
cancer patients has been prolonged, although the cancer survivors treated with RT has
increasing. Patients during/after RT often suffer from the RT-related toxicities including
radiation sickness, fatigue, nausea, vomiting, mucous membrane disorder, etc. These symp-
toms markedly reduce the physical activity level of patients and lead to deconditioning,
Total Surgery Nonsurgery
No. (%) (n = 70) No. (%) (n = 46) No. (%) (n = 24)
PS
Improved 49 (70.0) 45 (97.8) 4 (16.7)
Unchanged 13 (18.6) 1 (2.2) 12 (50.0)
Deteriorated 8 (11.4) 0 (0.0) 8 (33.3)
Redeteriorated 9 (12.9) 9 (20.0) 0 (0.0)
ADL
Improved 45 (64.3) 44 (95.7) 1 (4.2)
Unchanged 14 (20.0) 2 (4.3) 12 (50.0)
Deteriorated 11 (15.7) 0 (0.0) 11 (45.8)
Redeteriorated 9 (12.9) 9 (20.5) 0 (0.0)
PS, Eastern Cooperative Oncology Group Performance Status; ADL, activities of daily living.
Table 5. Outcomes of endpoints in patients undergoing surgical treatment and nonsurgical treatment.
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such as muscular weakness, flexibility deterioration, cardiorespiratory dysfunction and
psychological symptoms. Therefore, the rehabilitation intervention which increases the
physical activity level and prevents deconditioning is important. Mock et al. reported that
the walking exercise program during RT improved the physical functions, fatigue, emo-
tional distress and difficulty sleeping in breast cancer patients during RT [31]. And Segal
et al. showed that the resistance/aerobic training improved the QOL, aerobic fitness and
strength in prostate cancer patients during RT [32]. Also in the guidelines from American
College of Sports Medicine (ACSM) [33], the rehabilitation intervention recommended to
improve physical function, aerobic fitness, QOL and fatigue in cancer patients during/after
RT.
Furthermore, the number of elderly cancer patients treated with RT has been recently increas-
ing. The elderly patients who have sarcopenia and frailty easily suffer from RT-related toxic-
ities and deconditioning, then, decrease the completion rate of treatment [34], so the
rehabilitation should be positively applied to cancer patients during/after RT, especially for
elderly patients.
Moreover, the incidence of cancer survivors with bone metastasis has increased. Trouble-
some bone metastasis develops in 10–20% of patients with cancer. The majority of these
patients have an increased risk for skeletal-related events (SREs) including pathologic frac-
tures, spinal cord compression, the need for surgery, the need for RT and hypercalcemia [35].
SREs have been associated with significant morbidity, limited function and a decreased QOL
[36–38]. In particular, pathologic fractures and spinal cord compression restrict ADL. There-
fore, multidisciplinary team management of SREs (so-called bone management) is para-
mount in these patients. In these patients, rehabilitation over the course of treatment for the
prevention of SREs and improvement of ADL and QOL is a key aspect of “bone manage-
ment”.
5.1. Purpose of rehabilitation for patients with bone metastasis
The essential points of the rehabilitative interventions for patients with bone metastasis are as
follows [39]. (1) Rehabilitation aims to prevent patients from becoming bed-bound and helps
them to maintain as much independence as possible with regard to ADL. (2) Rehabilitation
commonly focuses on training patients to use their residual functions or to develop compen-
satory techniques by training in the use of assistive equipment or orthoses and educating both
patients and their family members to help them adjust to the altered way of life. (3) Rehabili-
tation has inherent risks such as pathologic fractures and spinal cord compression. Improve-
ments in physical function and physical activity levels due to rehabilitation might lead to an
increased risk of pathologic fracture during ADL. However, bed rest, as an alternative, has
various complications including muscle contractures, weakness and atrophy, orthostatic hypo-
tension, pressure sores, pneumonia, confusion and disorientation (so-called disuse syndrome).
Therefore, rehabilitation with the management of SREs risk would be more beneficial com-
pared with bed rest.
Radiotherapy12
5.2. Rehabilitative intervention paradigms
For patients with bone metastasis, rehabilitation mostly provides the adequate settlement of
bed rest angles, training for the use of orthoses, instructions for adequate movements for ADL
and exercises to maintain and increase physical function and ADL through discussion at bone
metastasis board.
5.2.1. Settlement of bed rest levels: spinal bone metastasis
In cases of pathologic fracture or fragility in the vertebral body (high risk of paralysis), the
head end of the Gatch bed should be raised by 30 degrees and patients wear a rigid spinal
brace. Patients are moved using the logroll technique without flexion or rotation of the spine.
In cases with a low risk of pathologic fracture (bone cortex remains), patients should wear a
rigid spinal brace, but there is no restriction on the bed rest angle.
5.2.2. Settlement of bed rest levels: pelvic/lower extremity bone metastasis
In the case of pathologic fracture or fragility in weight-bearing bones or joints, patients are
advised to avoid weight-bearing on the affected bone or joint. In patients with remaining bone
cortex and an absence of pain, there are no restrictions in ADL.
5.2.2.1. Introduction of orthoses
In patients with bone metastasis, orthoses are applied to decrease bone pain, prevent or treat
pathologic fractures and paralysis and to improve physical function. In patients with cervical
metastasis, in stable cases, a soft cervical collar is applied to restrict flexion and extend the
cervical vertebrae. In unstable cases, a Philadelphia collar and halo vest is applied to inhibit
flexion, extension, rotation and lateral bending of the cervical vertebrae. In patients with
thoracolumbar metastasis, spinal orthoses are applied to facilitate local rest by restricting the
flexion, extension, rotation and lateral bending of the spinal column, which helps to reduce
bone pain and inflammation, thereby reducing adverse psychological effects.
In the case of conservative treatment, a functional brace is applied to the humeral diaphyseal
fracture and a patellar tendon-bearing orthosis is applied to the weight-bearing bone or joint
below the lower leg. It takes a long time to increase bone strength, even after RT and long-term
nonweight bearing is necessary. Therefore, surgery should be considered for the bone metas-
tasis in the weight-bearing bones of the lower extremities.
5.2.2.2. Instructions for adequate movements
In the rehabilitation setting, to decrease the risk of the pathologic fractures and pain,
patients are instructed on how to move when conducting ADL. The examples are shown
in Table 6.
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5.2.2.3. Bone metastasis board
Under the concept of “bone management,” the multidisciplinary team approach is necessary
to achieve the early detection and treatment of bone metastasis and the clinical practice of
multidisciplinary therapy. In the treatment of bone metastasis, surgery, radiation therapy,
rehabilitation and pain control should be considered, so the multidisciplinary team should
discuss and decide the treatment plan in bone metastasis board. The necessity of rehabilitation
and orthosis, settlement of bed rest level and risk management are also discussed in bone
metastasis board, so the rehabilitation intervention can be safely provided to the bone meta-
static patients.
5.3. Efficacy of rehabilitation
Previous studies have reported that rehabilitation during multidisciplinary therapy
improved pain, physical function, ADL, QOL and prognosis in patients with bone metasta-
sis (Table 7). Ruff et al. [40] showed that patients with spinal epidural metastasis who
underwent rehabilitation had less pain, consumed less pain medication, were less
depressed and had a greater satisfaction with life, compared with those who did not
undergo rehabilitation. Other studies have reported that the rehabilitative intervention in
patients with bone metastases improved functional independence measure scores, progno-
sis, physical function (muscle strength, submaximal aerobic exercise capacity and ambula-
tion), physical activity level and QOL [41–44]. The rehabilitation with risk management by
the multidisciplinary team could be effective in preventing SREs and improving pain, ADL,
QOL and prognosis in patients with bone metastases. However, reports on the efficacy of
rehabilitation in patients with bone metastasis are limited and were usually conducted in
small populations. Therefore, further studies in larger populations are needed to validate
the efficacy of rehabilitation.
Examples
Daily life behaviors ·For patients with spinal bone metastasis, excess flexion, and rotation of the trunk should be
avoided in rolling over and getting up from bed.
·For patients with bone metastasis of the weight-bearing bones in the lower extremities and pelvis,
the transfer of motion with non-weight bearing should be instructed.
·In getting up from the bed, patients should use the automatic bed Gatch up function.
Assistive device ·A cane, crutch, or walker should be used to decrease pain and weight-bearing.
·Awheelchair should be used to decrease the physical burden in moving long distances.
·Self-help devices, such as a Sox aid, should be used to avoid the pain caused by trunk flexion.
Living environment ·Install handrails to decrease pain with ambulation.
adjustment ·Install handrails and higher toilet seats in the restroom to decrease pain and assist with standing up
from a seated position.
Table 6. Examples of instructions of movements for activities of daily living.
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6. Reirradiation for bone metastases
RT is one of the most useful modalities for pain relief in patients with bone metastases.
Although the American Society for Therapeutic Radiology and Oncology guidelines rec-
ommend 8 Gy in a single fraction as the standard method for palliative RT in uncompli-
cated painful bone metastases, reirradiation is required in 20–40% of cases [45, 46]. The
reirradiation rates are 2.5-fold higher after single fraction RT compared with after
multifraction RT [1]. Single fraction RT is commonly used for reirradiation. According to
the prospective randomized trial of reirradiation undertaken by the National Cancer
Institute of Canada Clinical Trial Group, single fraction RT of 8 Gy seemed to be
noninferior and less toxic than multifraction RT of 20 Gy [47]. The pain relief response
rate following reirradiation is 60–70%, with complete and partial responses of about 20
and 50%, respectively [46, 48], which are similar to the response rates seen with an initial
effective RT. Although initial responders are more likely to respond to reirradiation than
initial nonresponders, about half of the nonresponders can be expected to respond to
retreatment [48].
Reirradiation is also effective to maintain walking abilities of patients with MSCC. However,
the median duration of response is relatively short (about 4–5 months) [49, 50]. The degree of
motor function after reirradiation is associated with the walking ability before RT. More than
Author Subjects Study design Intervention Primary outcome Major results
Ruff [40] 42, spinal
epidural
metastasis
Controlled
retrospective
study
Training in transfers,
bowel and bladder
care, incentive
spirometry, nutrition,
and skin care
Pain, depression,
life satisfaction
Intervention group had less
pain, consumed less pain
medication, were less
depressed, and had greater
life satisfaction.
Tang [41] 63,
metastatic
spinal cord
compression
Retrospective
descriptive
study
Neuro-oncology
rehabilitation, tailored
to the needs of the
patient
Functional
independence
measure scores,
Tokuhashi score
Functional independence
measure score improved.
Longer survival in patients
with high Tokuhashi scores.
Cormie [42] 20, bone
metastatic
prostate
cancer
Randomized
controlled
study
Aerobic exercise and
resistance exercise
Fatigue, physical
function, body
composition
Physical function, physical
activity level, and lean mass
improved.
Jane [43] 72, bone
metastasis
Randomized
controlled
study
Massage: 3-month
training program
Pain intensity, sleep
quality, symptom
distress scale
Beneficial effects on pain,
mood, muscle relaxation, and
sleep quality.
Rief [44] 60, bone
metastasis
Randomized
controlled
study
Isometric resistance
training of the muscles
along the entire
vertebral column
Pain, concurrent
medication, oral
morphine
equivalent dose
Pain relief over a 6-months
period and reduced oral
morphine equivalent dose, as
well as concomitant pain
medication.
Table 7. Details of previous reports concerning rehabilitation for bone metastasis patients.
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80% of ambulant patients before RT will be expected to maintain the walking ability, whereas
less than 20% of not ambulant patients will recover the function [49, 50]. SBRT is well suited for
reirradiation of the spine due to its superiority of dose distribution compared with conven-
tional techniques. SBRT has a major potential to provide superior local control without increas-
ing toxicity (Table 8) [51–54]. A care must be taken when SBRT is applied to patients with
MSCC, because the existence of tumor too close to the spinal cord is a risk factor for local
recurrence due to underdose [51]. Relatively little is known regarding the long-term toxicities
of reirradiation. Because reirradiation has the potential to exceed normal tissue tolerance, it
might be appropriate to sum the biologically effective doses (BEDs) from the initial and repeat
treatment regimens to estimate the safety of treatment. The BED is calculated according to the
liner-quadratic model [BED = D × (1+ d/α/β), D: total dose, d: fractional dose] with generally
using α/β value of 2 (Gy2) for the late effects. For example, the BED for 30 Gy in 10 fractions is
75 Gy2 and 8 Gy in single fraction is 40 Gy2. Regarding the spinal cord, higher cumulative RT
doses (BED > 135.5 Gy2), higher doses for each RT course (BED > 98 Gy2) and a short interval
between the courses (<6 months) could be associated with a higher probability of developing
radiation-induced myelopathy [55]. These dose constraints for the spinal cord seem to be
reproducible in SBRT [56].
7. Beyond metal implant artifacts
Metallic surgical implants are commonly used in patients who undergo RT for bone metas-
tasis. In computed tomography, metallic hardware can dramatically attenuate the X-ray
beam and severe beam hardening effect and lead to faulty or inconsistent projection data
[57, 58]. Consequently, so-called metallic artifacts or bright and dark streak artifacts can
dramatically degrade the image quality. Figure 4 illustrates a typical case of a patient who
underwent spine-stabilization before adjacent RT. Strong artifacts induced by the titanium-
based pedicle screws make it difficult to distinguish target lesions from surrounding nor-
mal tissues.
Author
(year)
Patients/
lesions (n)
Previous EBRT
dose/Fx
Median dose/Fx (range) Local control Overall
survival
Neural
toxicity
Garg [52] 59/63 NA 30 Gy in 5 fx, 27 Gy in 3
fx
76% at 1 year 76% at 1
year
2 of G3
Radiculopathy
Mahadevan
[53]
60/81 30 Gy in 10 fx
(median)
24 Gy in 3 fx, 25–30 Gy in
5 fx
93% at last
follow-up
11 month
(median)
None
Hashmi
[54]
215/247 30 Gy in 10 fx
(median)
8-22 Gy in 1 fx, 14–50 Gy
in 3(2–20) fx
93% at 6
months
64% at 6
months
None
SBRT, Stereotactic body radiotherapy; EBRT, external beam radiotherapy; Fx, fraction; NA, not available; G3, grade3
Table 8. Outcomes of reirradiation by spinal SBRT.
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For modern-era RT protocols, target delineation and dose calculation are performed on CT
images using treatment-planning systems. Therefore, metallic artifacts, that are commonly
located directly adjacent to the target volume and organs-at-risk and that degrade the
delineation accuracy and dose calculation might lead to poor local control and a high risk of
complications. Several studies have investigated the metallic-implant-related dosimetric
impact using Monte Carlo simulations. Spadea et al. [59] reported that low-Z materials such
as titanium might not cause relevant dose discrepancies, while high-Z materials including
gold and platinum might lead to underestimation of the delivered dose during photon beam
irradiation. Verburg et al. [60] investigated the effect of titanium implants on dosimetric
errors in photon therapy treatment planning. They revealed dose discrepancies of up to
10% with range differences of up to 10 mm in artifact-contaminated areas. Figure 5 illus-
trates examples of dose differences caused by titanium-based artifacts introduced by
Verburg [58]. Factors including the beam-implant interaction, radiation beam type and the
physical characteristics of the metals differ and eventually lead to dose uncertainties. For
bone metastasis, especially in cases of infield recurrence of metastatic spinal lesions, the high
dosimetric accuracy for organs-at-risk becomes clinically significant because of the limited
spinal cord radiation tolerance. Recently, several promising approaches to reduce metallic
artifacts have been proposed, such as metal artifact reduction (MAR) algorithms [61–63] and
monoenergetic extrapolations from dual-energy computed tomography (DECT) [64, 65].
Figure 6 briefly illustrated reduction of metal artifacts using a frequency split MAR method
introduced by Meyer et al. Antiartifact approaches have proven useful for improving target
delineation and dose calculation in RT, but to date, they have not been widely implicated for
routine clinical use.
Figure 4. Artifacts of metallic surgical implants. (A) 2D radiography image shows a patient with implanted titanium
pedicle screws. (B) Computed tomography image of a patient with titanium pedicle screws. Streak artifacts are present
around the metallic implants.
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Figure 5. Differences in dose calculation of photon beams passing through the metal artifact region. (A) Dose calculation
on the artifact-affected computed tomography image. The arrow indicates the titanium insert. (B) Dose calculation on the
ground truth computed tomography image without the artifact.
Figure 6. Reduction of metal artifacts using a frequency split MAR method. (A) Patient with implanted pedicle screws.
(B) Patient with implanted unilateral hip endoprosthesis, Left: original computed tomography image; right: MAR
corrected computed tomography image.
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In conclusion, in cases of bone metastases, the impact of dose uncertainties due to metallic
implants is critical in modern RT, especially in patients undergoing reirradiation. Promising
antiartifact approaches might be useful options to achieve the anticipated magnitude of clinical
benefit.
8. Conclusion
RT plays a central role in the management of painful bone metastasis. Compared with
conventional RT, IMRT, or SBRT enables the delivery of higher doses to the target tumor
while minimizing the dose to adjacent organs. Not only pain relief but also the restoration
of spinal stability and preservation of neurologic function are associated with RT in patients
with spinal bone metastases. A multidisciplinary team, especially one consisting of a spinal
surgeon and rehabilitation physician, is particularly helpful for treating patients with spinal
bone metastases characterized by spinal instability. Reirradiation using IMRT or SBRT is a
valuable option for the management of bone metastasis. Future developments in surgical
procedures and RT will likely improve the management protocols for bone metastases and
technology to reduce metal artifacts in radiation planning might improve the efficacy and
safety of combination therapy.
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